INS and type 1 diabetes mellitus: Drawing on modeling outputs, the authors predicted greater efficacy for patients receiving a stable insulin dose than for those in whom the insulin dose was adjusted when starting treatment with empagliflozin; they also confirmed the efficacy of low-dose (i.e., 2.5 mg) empagliflozin in patients with T1D (Perkins et al., 2020; Johnston et al., 2021).